| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial | Lancet, The | 2019 | 425 |
| Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report | Therapeutic Drug Monitoring | 2019 | 163 |
| Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence | Cancer Treatment Reviews | 2019 | 163 |
| Cholangiocyte pathobiology | Nature Reviews Gastroenterology and Hepatology | 2019 | 155 |
| Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide | Gastroenterology | 2019 | 149 |
| Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials | Clinical Gastroenterology and Hepatology | 2019 | 116 |
| Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma | Gastroenterology | 2019 | 110 |
| Normothermic regional perfusion vs. super-rapid recovery in controlled donation after circulatory death liver transplantation | Journal of Hepatology | 2019 | 106 |
| Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial | Gut | 2019 | 100 |
| Biological membranes in EV biogenesis, stability, uptake, and cargo transfer: an ISEV position paper arising from the ISEV membranes and EVs workshop | Journal of Extracellular Vesicles | 2019 | 97 |
| Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme | Alimentary Pharmacology and Therapeutics | 2019 | 92 |
| Modification of the glycosylation of extracellular vesicles alters their biodistribution in mice | Nanoscale | 2019 | 86 |
| Insights into the success and failure of systemic therapy for hepatocellular carcinoma | Nature Reviews Gastroenterology and Hepatology | 2019 | 82 |
| Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis | Journal of Hepatology | 2019 | 80 |
| A202 TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 5.4 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS | Journal of the Canadian Association of Gastroenterology | 2019 | 78 |
| Clinical presentation, diagnosis and staging of cholangiocarcinoma | Liver International | 2019 | 77 |
| FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis | Journal of Hepatology | 2019 | 77 |
| Hepatic microcirculation and mechanisms of portal hypertension | Nature Reviews Gastroenterology and Hepatology | 2019 | 77 |
| Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study | The Lancet Gastroenterology and Hepatology | 2019 | 73 |
| Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study | Hepatology | 2019 | 73 |
| Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status. | Journal of Clinical Oncology | 2019 | 64 |
| Assessing the role of surface glycans of extracellular vesicles on cellular uptake | Scientific Reports | 2019 | 57 |
| Dual Targeting of Histone Methyltransferase G9a and DNA-Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma | Hepatology | 2019 | 56 |
| Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline | Journal of Bone and Mineral Research | 2019 | 51 |
| Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation | Gastroenterology | 2019 | 50 |
